硼替佐米联合化疗治疗原发性浆细胞白血病一例并文献复习
被引量：1
摘要
目的探讨硼替佐米联合化疗治疗原发性浆细胞白血病（PCL）的疗效。方法报告一例原发性PCL患者使用硼替佐米联合化疗的临床资料，并文献复习。原发性PCL患者常规化疗无效，PCL病情进展，使用硼替佐米联合化疗（硼替佐米＋地塞米松＋沙利度胺）治疗。结果经过硼替佐米联合化疔治疗2个疗程后，患者获得完全缓解（CR）。其后患者又接受2个疗程硼替佐米联合化疗，保持在CR状态。结论硼替佐米联合化疗治疗PCL有效。
出处
《白血病．淋巴瘤》
CAS
2008年第5期374-376,共3页
Journal of Leukemia & Lymphoma
参考文献14
-
1Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma[J]. Leukemia, 2006, 20(9): 1467-1473.
-
2Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics[J]. Blood, 1999, 93(3): 1032-1037.
-
3Smadja NV, Bastard C, Brigaudeau C. Primary plasma cell leukemia and multiple myeloma: one or two diseases according to the methodology[J]. Blood, 1999, 94(10): 3607-3609.
-
4Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:final time-to-event results from the SUMMIT trial[J]. Cancer, 2006, 106 (6): 1316-1319.
-
5Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study [J]. Blood, 2006, 108(7): 2165-2172.
-
6Esparts-Ogando A, Alegre A, Aguado B, et al. Borteznmib is an efficient agent in plasma cell leukemias[J]. Int J Cancer, 2005, 114 (4): 665-667.
-
7Ali R, Beksac M, Ozkalemkas F, et al. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia [J]. Leuk Lymphoma, 2007, 48(7): 1426-1428.
-
8Kim S J, Kim J, Cho Y, et al. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia[J]. Jpn J Clin Oncol, 2007, 37(5): 382- 384.
-
9Finnegan DP, Kettle P, Drake M, et al. Bortezomib is effective in primary plasma cell leukemia[J]. Leuk Lymphoma, 2006, 47(8): 1670-1673.
-
10Capalbo S, Chiefa A, Delia M, et al. Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement[J]. Acta Oneol, 2007, 46(2): 262-264.
同被引文献17
-
1International Myeloma Working Group. Criteria for the classification ofmonoclonal gammopathies,multiple myeloma and related disorders : areport of the International Myeloma Working Group [ J ]. Br JHaematol, 2003,121(5) : 749-757.
-
2Avet-Loiseau H, Roussel M, Campion L, et al. Cytogenetic andtherapeutic characterization of primary plasma cell leukemia : the IFMexperience [ J ]. Leukemia, 2012, 26 ( 1 ): 158-159. DOI:10.1038/Ieu.2011.176.
-
3Katodritou E, Verrou E, Gastari V, et al. Response of primaryplasma cell leukemia to the combination of bortezomib anddexamethasone : do specific cytogenetic and immunophenotypiccharacteristics influence treatment outcome. [ J ]. Leuk Res,2008,32(7): 1153-1156.
-
4Pagano L,Valentini CG, de Stefano V, et al. Primary plasma cellleukemia: a retrospective multicenter study of 73 patients [ J ]. AnnOncol,2011, 22(7) : 1628-1635. DOI: 10.1093/annonc/mdq646.
-
5Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cellleukemia : report of 17 new cases treated with autologous or allogeneicstem-cell transplantation and review of the literature [ J ]. Am JHematol, 2005, 78 (4 ) : 288-294. DOI: 10.1002/ajh.20272.
-
6Colovic M, Jankovic G, Suvajdzic N, et al. Thirty patients withprimary plasma cell leukemia: a singe center experience [ J ] . MedOncol, 2008, 25(2): 154-160. DOI: 10.1007/sl2032-007-9011-5.
-
7Drake MB,Iacobelli S,van Biezen A, et al. Primary plasma cellleukemia and autologous stem cell transplantation [ J ].Haematologica, 2010, 95 (5): 804-809. DOI:10.3324/haematol.2009.013334.
-
8Garcla-Sanz R, Orfao A, Gonzalez M,et al. Primary plasma cellleukemia: clinical, immunophenotypic, DNA ploidy, andcytogenetic characteristics [ J ]. Blood, 1999,93(3): 1032-1037.
-
9Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrationsand survival in plasma cell leukemia [ J ]. Leukemia, 2008,22 (5 ):1044-1052. D01:10.1038/leu.2008.4.
-
10Vela-Ojeda J, Garcla-Ruiz Esparza MA, Rosas-Cabral A, et al.Intermediate doses of melphalan and dexamethasone are better thanvincristine, adriamycin, and dexamethasone ( VAD ) andpolychemotherapy for the treatment of primary plasma cell leukemia[J]. Ann Hematol, 2002, 81 (7): 362-367. DOI:10.1007/s00277-002-0480-5.
-
1赖若梅.原发性浆细胞白血病的临床特征及治疗[J].中国医药指南,2012,10(29):158-159. 被引量：1
-
2张月仙,严国栋.原发性浆细胞白血病一例报告[J].实用医技杂志,1996,3(5):389-390.
-
3欧阳桂芳,林茂芳.原发性浆细胞白血病3例报告及文献复习[J].实用肿瘤杂志,2007,22(1):68-70. 被引量：3
-
4王欢,李迎春,廖爱军,刘卓刚,张嵘,韩乃英.7例原发性浆细胞白血病临床治疗分析[J].中国医科大学学报,2006,35(5):555-556. 被引量：4
-
5王真勤,王爱丽.原发性浆细胞白血病一例[J].江西医学检验,1998,16(4):202-202.
-
6杨仁池,钱林生,卞寿庚.原发性浆细胞白血病(附11例报告)[J].白血病,1999,8(6):333-335. 被引量：2
-
7梁勇,王会朋,杨淑莲.来那度胺联合化疗治疗原发性浆细胞白血病1例分析[J].中国误诊学杂志,2012,12(11):2725-2725.
-
8包阿巾,高海艳,周艳红,李志.反应停加联合化疗治疗原发性浆细胞白血病1例[J].白血病．淋巴瘤,2003,12(5):290-290.
-
9杨弘,李云涛.原发性浆细胞白血病临床特征与最佳治疗方案探讨[J].亚太传统医药,2013,9(3):125-126. 被引量：2
-
10窦翠云,李士平,盛丽,牛焕付.原发性浆细胞白血病2例[J].现代诊断与治疗,2003,14(6):382-382.
